Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianguang, Zheng, Huifang, Diao, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358726/
https://www.ncbi.nlm.nih.gov/pubmed/30646574
http://dx.doi.org/10.3390/ijms20020317
_version_ 1783392049415847936
author Zhang, Jianguang
Zheng, Huifang
Diao, Yong
author_facet Zhang, Jianguang
Zheng, Huifang
Diao, Yong
author_sort Zhang, Jianguang
collection PubMed
description Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy.
format Online
Article
Text
id pubmed-6358726
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63587262019-02-06 Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy Zhang, Jianguang Zheng, Huifang Diao, Yong Int J Mol Sci Review Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy. MDPI 2019-01-14 /pmc/articles/PMC6358726/ /pubmed/30646574 http://dx.doi.org/10.3390/ijms20020317 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhang, Jianguang
Zheng, Huifang
Diao, Yong
Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title_full Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title_fullStr Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title_full_unstemmed Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title_short Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
title_sort natural killer cells and current applications of chimeric antigen receptor-modified nk-92 cells in tumor immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358726/
https://www.ncbi.nlm.nih.gov/pubmed/30646574
http://dx.doi.org/10.3390/ijms20020317
work_keys_str_mv AT zhangjianguang naturalkillercellsandcurrentapplicationsofchimericantigenreceptormodifiednk92cellsintumorimmunotherapy
AT zhenghuifang naturalkillercellsandcurrentapplicationsofchimericantigenreceptormodifiednk92cellsintumorimmunotherapy
AT diaoyong naturalkillercellsandcurrentapplicationsofchimericantigenreceptormodifiednk92cellsintumorimmunotherapy

Ejemplares similares